Skip to main content
Blood Cancer Journal logoLink to Blood Cancer Journal
. 2021 Feb 1;11(2):28. doi: 10.1038/s41408-021-00413-7

Author Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study

Franco Locatelli 1, Gerhard Zugmaier 2,, Noemi Mergen 2, Peter Bader 3, Sima Jeha 4, Paul-Gerhardt Schlegel 5, Jean-Pierre Bourquin 6, Rupert Handgretinger 7, Benoit Brethon 8, Claudia Rossig 9, Christiane Chen-Santel 10
PMCID: PMC7873230  PMID: 33563903

Correction to: Blood Cancer Journal

10.1038/s41408-020-00342-x published online 24 July 2020

The original version of the article contained an error in Fig. 1b, which showed that 57/69 (78.3%) of patients with CR in the first 2 cycles achieved MRD response. The article has now been corrected to state 57/69 (82.6%).

graphic file with name 41408_2021_413_Fig1_HTML.jpg

Fig. 1


Articles from Blood Cancer Journal are provided here courtesy of Nature Publishing Group

RESOURCES